Notizie AIOM – anno XVII n. 709 – Pagina 2

8 Febbraio 2019

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary results have suggested that ...
Leggi tutto

8 Febbraio 2019

A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy

E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of nicotine products approved as smoking-cessation treatments. We randomly assigned adults attending U.K. National Health Service stop-smoking ...
Leggi tutto

8 Febbraio 2019

4 febbraio 2019 – Comunicazione EMA sul rischio di sanguinamento associato agli anticoagulanti orali ad azione diretta

8 Febbraio 2019

6 febbraio 2019 – Comitato per i Medicinali per Uso umano (CHMP) dell’EMA: highlights del meeting di gennaio

8 Febbraio 2019

World Cancer Day 2019: Emphasis on Early Detection

February 4, 2019 - World Cancer Day 2019 -February 4- highlights the need for urgent action to increase early-stage cancer detection, screening, and diagnosis to significantly improve patients’ chances of survival. Taking place with the theme of “I Am and I Will,” ...
Leggi tutto

8 Febbraio 2019

More Than 60 Leading Health-Care Organizations Call on CMS to Maintain Coverage for Medically Necessary Cancer Testing

February 7, 2019 - Leading health-care companies and organizations representing patients, providers, academic medical centers, laboratories, and diagnostic manufacturers urged the Centers for Medicare & Medicaid Services (CMS) to revise its interpretation of the National ...
Leggi tutto

8 Febbraio 2019

FDA Grants Priority Review to Pexidartinib for Tenosynovial Giant Cell Tumor

February 5, 2019 - The FDA has granted a priority review designation to a new drug application (NDA) for the investigational, small molecule, CSF1R receptor inhibitor pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). ...
Leggi tutto

8 Febbraio 2019

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s continuing efforts to educate patients on known risk of lymphoma from breast implants

February 6, 2019 - One of the most important roles we have as a public health agency is educating patients and health care providers about both the benefits and risks of medical products, including breast implants. I know there are many choices of breast implants available ...
Leggi tutto

8 Febbraio 2019

FDA Schedules ODAC Meeting for Selinexor in Penta-Refractory Myeloma

February 7, 2019 - The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2019, to discuss a new drug application (NDA) for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma. ...
Leggi tutto

8 Febbraio 2019

FDA takes new steps to adopt more modern technologies for improving the security of the drug supply chain through innovations that improve tracking and tracing of medicines

February 7, 2019 - A key element of the U.S. Food and Drug Administration’s mission is focused on helping to ensure that all products we regulate, including drugs available to consumers, are safe and of high quality. This means working to ensure greater accountability ...
Leggi tutto

LAVORIAMO CON

News

TUMORE DEL RENE: ARRIVA “IL FILO DI ARIANNA” LE STORIE DI CHI È ENTRATO NEL LABIRINTO DELLA MALATTIA

TUMORE DEL PANCREAS, DARAXONRASIB NON ANCORA DISPONIBILE IN ITALIA. AIOM: “SIA AVVIATO SUBITO IL PROGRAMMA DI USO COMPASSIONEVOLE”

BRISTOL MYERS SQUIBB PRESENTA AL CONGRESSO 2026 DELLA EUROPEAN SOCIETY OF CARDIOLOGY (ESC) I DATI FINO A CINQUE ANNI CHE RAFFORZANO L’EFFICACIA E LA SICUREZZA A LUNGO TERMINE DI MAVACAMTEN NELLA CARDIOMIOPATIA IPERTROFICA OSTRUTTIVA (OHCM) SINTOMATICA

BPCO – TOZORAKIMAB DIMOSTRA UNA RIDUZIONE STATISTICAMENTE SIGNIFICATIVA E DI ELEVATA RILEVANZA CLINICA DELLE RIACUTIZZAZIONI NEGLI STUDI DI FASE III OBERON E TITANIA

I GRUPPI DI MELISI E RENI VINCITORI DEL BANDO DI RICERCA PROMOSSO DA FONDAZIONE UMBERTO VERONESI ETS E FICOG SUL TUMORE AL PANCREAS

TUMORE DEL SENO, IN 5 ANNI PRESCRITTI IN ITALIA 30MILA TEST GENOMICI. GLI ESPERTI: “ESAMI SEMPRE PIU’ EFFICACI PER PERSONALIZZARE LE TERAPIE”

TUMORI: “LA DECISIONE DEL MOLECULAR TUMOR BOARD MIGLIORA IL TEMPO DI CONTROLLO DELLA MALATTIA. OGNI ANNO IN ITALIA 15.000 PAZIENTI CANDIDATI A PROFILAZIONE GENOMICA ESTESA”

Notizie AIOM – anno XVII n. 709

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy

4 febbraio 2019 – Comunicazione EMA sul rischio di sanguinamento associato agli anticoagulanti orali ad azione diretta

6 febbraio 2019 – Comitato per i Medicinali per Uso umano (CHMP) dell’EMA: highlights del meeting di gennaio

World Cancer Day 2019: Emphasis on Early Detection

More Than 60 Leading Health-Care Organizations Call on CMS to Maintain Coverage for Medically Necessary Cancer Testing

FDA Grants Priority Review to Pexidartinib for Tenosynovial Giant Cell Tumor

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s continuing efforts to educate patients on known risk of lymphoma from breast implants

FDA Schedules ODAC Meeting for Selinexor in Penta-Refractory Myeloma

FDA takes new steps to adopt more modern technologies for improving the security of the drug supply chain through innovations that improve tracking and tracing of medicines